These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34959252)

  • 21. Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms.
    Shiseki M; Masuda A; Watanabe N; Fujii M; Kimura T; Yoshinaga K; Mori N; Teramura M; Motoji T
    Hematol Rep; 2011 Aug; 3(2):e10. PubMed ID: 22184531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The epidemiology of Waldenström macroglobulinemia.
    McMaster ML
    Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases].
    Chen Y; Zhang F; Wu HM; Luo XL; Zhang KP; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2021 Dec; 50(12):1346-1352. PubMed ID: 34865422
    [No Abstract]   [Full Text] [Related]  

  • 24. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
    Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
    Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
    Brandefors L; Melin B; Lindh J; Lundqvist K; Kimby E
    Br J Haematol; 2018 Nov; 183(4):564-577. PubMed ID: 30198549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
    Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.
    Kristinsson SY; Goldin LR; Turesson I; Björkholm M; Landgren O
    Acta Haematol; 2012; 127(3):173-7. PubMed ID: 22310551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
    Naderi N; Yang DT
    Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Waldenström macroglobulinemia: Japanese perception].
    Sekiguchi N
    Rinsho Ketsueki; 2019; 60(8):988-997. PubMed ID: 31484900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.
    Dalal NH; Dores GM; Curtis RE; Linet MS; Morton LM
    Br J Haematol; 2020 Jun; 189(6):1107-1118. PubMed ID: 32090327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden.
    Brandefors L; Kimby E; Lundqvist K; Melin B; Lindh J
    Acta Oncol; 2016; 55(1):91-8. PubMed ID: 26559865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
    Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig WD; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
    Leukemia; 2009 Jan; 23(1):153-61. PubMed ID: 18818699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.
    Cao X; Medeiros LJ; Xia Y; Wang X; Thomas SK; Loghavi S; Li X; Shah JJ; Gustafson SA; Weber DM; Miranda RN; Xu-Monette ZY; Orlowski RZ; Young KH
    Leuk Lymphoma; 2016 May; 57(5):1104-13. PubMed ID: 26421453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lymphoplasmacytic lymphoma with Waldenström's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].
    Liang DN; Li GD; Dai L; Huang J; Wang WY; Feng WH; Li FY; Liao DY
    Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):728-32. PubMed ID: 20079010
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
    J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
    [No Abstract]   [Full Text] [Related]  

  • 36. Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
    Vajdic CM; Landgren O; McMaster ML; Slager SL; Brooks-Wilson A; Smith A; Staines A; Dogan A; Ansell SM; Sampson JN; Morton LM; Linet MS
    J Natl Cancer Inst Monogr; 2014 Aug; 2014(48):87-97. PubMed ID: 25174029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
    Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
    Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The efficacy and safety of ibrutinib in the treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].
    Huang YS; Xiong WJ; Yuan JJ; Yu Y; Li YX; Yan YT; Wang TY; Lyu R; Liu W; An G; Zhao YZ; Zou DH; Qiu LG; Yi SH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):755-760. PubMed ID: 39307722
    [No Abstract]   [Full Text] [Related]  

  • 40. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
    Wang W; Lin P
    Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.